Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee

June 13, 2005

Briefing Information

The committee will discuss the Implications of recently available data related 
to the safety of long-acting beta-agonist bronchodilators.


The statements contained in this document(s) are those of the product's sponsor, not FDA,
and FDA does not necessarily agree with the sponsor's statements..


Novartis Pharmaceuticals Corporation
Novartis Appendix 1
Novartis Appendix 2



Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. 552).
These redacted portions will appear as white space on the screen or on the printed page.

FDA Background Material Index